<table border="0" cellpadding="0" cellspacing="0" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 6: Clinically Significant Drug Interactions with Paricalcitol 
			</caption>
<colgroup>
<col width="18.7%"></col>
<col width="81.3%"></col>
</colgroup>
<tbody>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">CYP3A Inhibitors </content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Paricalcitol is partially metabolized by CYP3A. Hence, exposure of paricalcitol will increase upon coadministration with strong CYP3A inhibitors such as but not limited to: boceprevir, clarithromycin, conivaptan, grapefruit juice, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Dose adjustment of paricalcitol capsules may be necessary. Monitor closely for iPTH and serum calcium concentrations, if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor. <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Cholestyramine </content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact </content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of paricalcitol. <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention </content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Recommend to take paricalcitol capsules at least 1 hour <content stylecode="underline">before</content> or 4 to 6 hours <content stylecode="underline">after</content> taking cholestyramine (or at as great an interval as possible) to avoid impeding absorption of paricalcitol.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Mineral Oil </content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Mineral oil or other substances that may affect absorption of fat may influence the absorption of paricalcitol.<br/>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Recommend to take paricalcitol capsules at least 1 hour <content stylecode="underline">before</content> or 4 to 6 hours <content stylecode="underline">after</content> taking mineral oil (or at as great an interval as possible) to avoid affecting absorption of paricalcitol. <br/>
</td>
</tr>
</tbody>
</table>